Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 1
2014 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

2 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Clinical and endocrine correlates of circulating sclerostin levels in patients with type 1 diabetes mellitus.
Neumann T, Hofbauer LC, Rauner M, Lodes S, Kästner B, Franke S, Kiehntopf M, Lehmann T, Müller UA, Wolf G, Hamann C, Sämann A. Neumann T, et al. Clin Endocrinol (Oxf). 2014 May;80(5):649-55. doi: 10.1111/cen.12364. Epub 2013 Dec 12. Clin Endocrinol (Oxf). 2014. PMID: 24237244
AIM: Type 1 diabetes mellitus (T1DM) increases fragility fractures due to low bone mass, micro-architectural alterations and decreased bone formation. ...CONCLUSIONS: Sclerostin serum levels were increased in patients with T1DM, an …
AIM: Type 1 diabetes mellitus (T1DM) increases fragility fractures due to low bone mass, micro-architectural alt …
Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes.
Gennari L, Merlotti D, Valenti R, Ceccarelli E, Ruvio M, Pietrini MG, Capodarca C, Franci MB, Campagna MS, Calabrò A, Cataldo D, Stolakis K, Dotta F, Nuti R. Gennari L, et al. J Clin Endocrinol Metab. 2012 May;97(5):1737-44. doi: 10.1210/jc.2011-2958. Epub 2012 Mar 7. J Clin Endocrinol Metab. 2012. PMID: 22399511
CONTEXT: Previous observations showed a condition of low bone turnover and decreased osteoblast activity in both type 1 and 2 diabetes mellitus (DM1 and DM2). Sclerostin is a secreted Wnt antagonist produced by osteocytes that regulates osteobla …
CONTEXT: Previous observations showed a condition of low bone turnover and decreased osteoblast activity in both type 1 and 2 …